Migdal Insurance & Financial Holdings Ltd. Zai Lab LTD Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.97 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$81.94 - $135.34 $307,029 - $507,118	-3,747 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$73.3 - $89.48 $139,050 - $169,743	1,897 Added 102.54%	3,747 $309,000
Q2 2020 Aug 11, 2020	BUY	$48.82 - $82.53 $90,317 - $152,680	1,850 New	1,850 $153,000

Others Institutions Holding ZLAB

# of Institutions

146

Shares Held

53M

Call Options Held

103K

Put Options Held

439K

Wellington Management Group LLP Boston, MA

6.66M
Shares

$234 Million
0.03% of portfolio
Janus Henderson Group PLC London, X0

6.57M
Shares

$230 Million
0.09% of portfolio
Capital World Investors Los Angeles, CA

6.43M
Shares

$226 Million
0.03% of portfolio
Morgan Stanley New York, NY

3.17M
Shares

$111 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

2.51M
Shares

$88 Million
1.07% of portfolio

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.44B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account